Costs of drugs for treatment of rheumatic diseases

The cost of drugs is becoming an issue worldwide, in particular for inflammatory rheumatic diseases. In the current review, an overview of the scene is given with a specific emphasis on accessibility for those patients in real need of the available expensive treatments. The authors propose 7 princip...

Descripción completa

Detalles Bibliográficos
Autores principales: Westhovens, Rene, Annemans, Lieven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Inflammatory Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020678/
https://www.ncbi.nlm.nih.gov/pubmed/27651923
http://dx.doi.org/10.1136/rmdopen-2016-000259
_version_ 1782453249569193984
author Westhovens, Rene
Annemans, Lieven
author_facet Westhovens, Rene
Annemans, Lieven
author_sort Westhovens, Rene
collection PubMed
description The cost of drugs is becoming an issue worldwide, in particular for inflammatory rheumatic diseases. In the current review, an overview of the scene is given with a specific emphasis on accessibility for those patients in real need of the available expensive treatments. The authors propose 7 principles for discussion that need to be addressed and are a responsibility for all stakeholders in rheumatology.
format Online
Article
Text
id pubmed-5020678
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50206782016-09-20 Costs of drugs for treatment of rheumatic diseases Westhovens, Rene Annemans, Lieven RMD Open Inflammatory Arthritis The cost of drugs is becoming an issue worldwide, in particular for inflammatory rheumatic diseases. In the current review, an overview of the scene is given with a specific emphasis on accessibility for those patients in real need of the available expensive treatments. The authors propose 7 principles for discussion that need to be addressed and are a responsibility for all stakeholders in rheumatology. BMJ Publishing Group 2016-09-12 /pmc/articles/PMC5020678/ /pubmed/27651923 http://dx.doi.org/10.1136/rmdopen-2016-000259 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Inflammatory Arthritis
Westhovens, Rene
Annemans, Lieven
Costs of drugs for treatment of rheumatic diseases
title Costs of drugs for treatment of rheumatic diseases
title_full Costs of drugs for treatment of rheumatic diseases
title_fullStr Costs of drugs for treatment of rheumatic diseases
title_full_unstemmed Costs of drugs for treatment of rheumatic diseases
title_short Costs of drugs for treatment of rheumatic diseases
title_sort costs of drugs for treatment of rheumatic diseases
topic Inflammatory Arthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020678/
https://www.ncbi.nlm.nih.gov/pubmed/27651923
http://dx.doi.org/10.1136/rmdopen-2016-000259
work_keys_str_mv AT westhovensrene costsofdrugsfortreatmentofrheumaticdiseases
AT annemanslieven costsofdrugsfortreatmentofrheumaticdiseases

Ejemplares similares